Comparative Effects of Ustekinumab and Vedolizumab on Alopecia in Ulcerative Colitis: A Systematic Review and Meta-Analysis

This systematic review and meta-analysis compared the effects of ustekinumab and vedolizumab on alopecia outcomes in patients with ulcerative colitis. The study included 18 studies with sample sizes ranging from single case reports to systematic reviews involving over 2,200 patients. Results showed that ustekinumab and vedolizumab had variable effects on hair loss, with some patients experiencing significant regrowth and others experiencing worsening alopecia. Pooled analysis revealed that 65.5% of patients achieved hair regrowth, and active therapy increased the odds of achieving a SALT score ≥50. Adverse events were generally mild, but relapse was common. The study concludes that while these biologics may offer therapeutic potential for alopecia in select cases, their effects are inconsistent and require further investigation through large, randomized trials.